temozolomide
Temodar	Pharmaceutical company: Schering Corporation www.temodar.com

NEW INDICATION & DOSAGE
Newly diagnosed glioblastoma multiforme in combination with radiation therapy—
Adults: Initially, 75 mg/m² I.V. infusion or P.O. daily for 42 days. Maintenance dose, 150 mg/m² I.V. infusion or P.O. on days 1 to 5 of a 28-day cycle for six cycles; may increase dose to 200 mg/m² for cycles two through six if common toxicity criteria (CTC) is grade 2 or less, absolute neutrophil count (ANC) is 1.5 × 10⁹/L or more, and platelet count is 100 × 10⁹/L or more. If dose was increased in cycle two, maintain dose at 200 mg/m² for days 1 to 5 of subsequent cycles, unless toxicity occurs. If dose wasn't increased in cycle two, don't increase in subsequent cycles.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins,
publisher of Lippincott's Nursing Drug Guide.
For help on how you should use this site, see our Disclaimer.

© Copyright 2010 by Lippincott Williams & Wilkins